429 related articles for article (PubMed ID: 24962757)
21. Long-lasting protective immunity against H7N9 infection is induced by intramuscular or CpG-adjuvanted intranasal immunization with the split H7N9 vaccine.
Zhou Y; Li S; Bi S; Li N; Bi Y; Liu W; Wang B
Int Immunopharmacol; 2020 Jan; 78():106013. PubMed ID: 31806571
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.
Madan A; Ferguson M; Rheault P; Seiden D; Toma A; Friel D; Soni J; Li P; Innis BL; Schuind A
Vaccine; 2017 Apr; 35(15):1865-1872. PubMed ID: 28302407
[TBL] [Abstract][Full Text] [Related]
23. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial.
Wu UI; Hsieh SM; Lee WS; Wang NC; Kung HC; Ou TY; Chen FL; Lin TY; Chen YC; Chang SC
Vaccine; 2017 Jul; 35(33):4099-4104. PubMed ID: 28668573
[TBL] [Abstract][Full Text] [Related]
25. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations.
Miyaki C; Quintilio W; Miyaji EN; Botosso VF; Kubrusly FS; Santos FL; Iourtov D; Higashi HG; Raw I
Vaccine; 2010 Mar; 28(13):2505-9. PubMed ID: 20123051
[TBL] [Abstract][Full Text] [Related]
26. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
27. Systemic and mucosal humoral immune responses induced by the JY-adjuvanted nasal spray H7N9 vaccine in mice.
Xu J; Li S; Wang X; Liu J; Shan P; Zhou Y; Zhao J; Wang Z; Xu C; Chen M; Chen Z; Zhao K; Qu D
Emerg Microbes Infect; 2018 Aug; 7(1):140. PubMed ID: 30076293
[TBL] [Abstract][Full Text] [Related]
28. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
[TBL] [Abstract][Full Text] [Related]
29. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
El Sahly HM; Atmar RL; Patel SM; Bellamy A; Liu L; Hong W; Zhu H; Guan Y; Keitel WA;
Vaccine; 2019 May; 37(19):2561-2568. PubMed ID: 30955980
[TBL] [Abstract][Full Text] [Related]
31. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
32. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
33. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
Andrews NJ; Walker WT; Finn A; Heath PT; Collinson AC; Pollard AJ; Snape MD; Faust SN; Waight PA; Hoschler K; Sheasby L; Waddington C; Kerridge S; Chalk J; Reiner A; John T; Fletcher M; Allen R; Fineman N; Wilkins S; Casey M; Michaelis L; Oeser C; Okike I; Ladhani S; Miller E
Vaccine; 2011 Oct; 29(45):7913-9. PubMed ID: 21875635
[TBL] [Abstract][Full Text] [Related]
34. The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.
Wu XX; Deng XL; Yu DS; Yao W; Ou HL; Weng TH; Hu CY; Hu FY; Wu NP; Yao H; Zhang FC; Li LJ
Cell Physiol Biochem; 2018; 46(2):633-643. PubMed ID: 29617693
[TBL] [Abstract][Full Text] [Related]
35. Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.
Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
PLoS One; 2016; 11(3):e0150678. PubMed ID: 26930068
[TBL] [Abstract][Full Text] [Related]
36. Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development.
Chen TH; Liu YY; Jan JT; Huang MH; Spearman M; Butler M; Wu SC
Antiviral Res; 2017 Oct; 146():213-220. PubMed ID: 28947234
[TBL] [Abstract][Full Text] [Related]
37. IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection.
Valkenburg SA; Li OT; Mak PW; Mok CK; Nicholls JM; Guan Y; Waldmann TA; Peiris JS; Perera LP; Poon LL
Proc Natl Acad Sci U S A; 2014 Apr; 111(15):5676-81. PubMed ID: 24706798
[TBL] [Abstract][Full Text] [Related]
38. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
39. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
[TBL] [Abstract][Full Text] [Related]
40. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.
Forrest HL; Khalenkov AM; Govorkova EA; Kim JK; Del Giudice G; Webster RG
Vaccine; 2009 Jun; 27(31):4187-95. PubMed ID: 19406182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
